Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials

Fact checked by" Roman Fabbricatore
News
Article

Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.

"With an acceptable safety profile manageable in routine urologic practice, [mitomycin] is administered in an outpatient setting without the need for general anesthesia. This review article highlights the clinical evidence supporting [mitomycin’s] role as an innovative option for patients with recurrent LG-IR-NMIBC," according to study author Sandip M. Prasad, MD, MPhil.

"With an acceptable safety profile manageable in routine urologic practice, [mitomycin] is administered in an outpatient setting without the need for general anesthesia. This review article highlights the clinical evidence supporting [mitomycin’s] role as an innovative option for patients with recurrent LG-IR-NMIBC," according to study author Sandip M. Prasad, MD, MPhil.

The intravesical mitomycin solution (Zusduri; formerly UGN-102) elicited durable responses and manageable safety across multiple populations of patients with recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer (LG-IR-NMIBC), according to findings from a review article published in Reviews in Urology.1

Authors of the review article compiled data from 3 studies assessing treatment with the mitomycin solution: the phase 2b OPTIMA II trial (NCT03558503), the phase 3 ATLAS trial (NCT04688931), and the phase 3 ENVISION trial (NCT05243550).2-4

“[The mitomycin solution] is an FDA-approved, non-surgical treatment that has consistently demonstrated robust, clinically significant, and durable complete responses [CRs] in patients with recurrent LG-IR-NMIBC,” lead study author Sandip M. Prasad, MD, MPhil, director of Genitourinary Surgical Oncology and Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, stated in a press release on these findings.5 “With an acceptable safety profile manageable in routine urologic practice, [mitomycin] is administered in an outpatient setting without the need for general anesthesia. This review article highlights the clinical evidence supporting [mitomycin’s] role as an innovative option for patients with recurrent LG-IR-NMIBC.”

OPTIMA II Trial

Data from OPTIMA II showed a 3-month CR rate of 65.1% (95% CI, 52.0%-76.7%). Additionally, the median duration of response (DOR) was not reached (NR) at the 12-month cutoff, although the estimated probability of a sustained response at 9 months after CR was 69.9% (95% CI, 51.8%-82.3%).

In a 5-year follow-up analysis including 41 patients with a CR in the parent study, the median estimated DOR was 24.2 months (95% CI, 9.7-42.1) after a median follow-up of 35.8 months (95% CI, 10.8-61.0). After a median follow-up of 50.4 months (95% CI, 27.0-not estimable [NE]) among 17 patients with long-term follow-up data, the median DOR was 42.1 months (95% CI, 24.2-NE).

Investigators reported that treatment-emergent adverse effects (TEAEs) typically showed mild or moderate severity. Common TEAEs in this population included dysuria (41.3%), pollakiuria (20.6%), and hematuria (15.9%).

In the open-label phase 2b OPTIMA II trial, 63 patients with LG-IR-NMIBC received at least 1 instillation of mitomycin. The trial’s primary end point was the CR rate. A key secondary end point was durable CRs in patients who achieved a CR at the 3-month visit.

ATLAS Trial

Of 396 patients screened for the ATLAS trial, 142 received mitomycin with or without transurethral resection of bladder tumor (TURBT), and 140 underwent TURBT alone. Three-month CRs were observed in 64.8% (95% CI, 56.3%-72.6%) who received mitomycin at baseline and 62.1% (95% CI, 53.6%-70.2%) who received TURBT at baseline. Furthermore, the estimated 12-month DOR rates after CR were 79.6% (95% CI, 69.3%-86.8%) in the mitomycin arm and 69.6% (95% CI, 57.6%-78.9%) in the TURBT alone arm; outcomes favored the mitomycin arm (HR, 0.49; 95% CI, 0.26-0.93).

TEAEs occurred in 75.4% of the mitomycin arm and 47.7% in the TURBT alone arm. In each respective arm, the most common TEAEs included dysuria (30.4% vs 4.5%), nocturia (18.1% vs 6.8%), and micturition urgency (18.1% vs 7.6%).

The primary end point of the ATLAS trial was disease-free survival. Secondary end points included the CR rate and DOR.

ENVISION Trial

Findings from the ongoing, prospective ENVISION trial showed that among 240 patients who received at least 1 instillation of mitomycin, 79.6% (95% CI, 73.9%-84.5%) achieved a CR at 3 months. Among those with a response, the probability of disease-free status at 12 months was 82.3% (95% CI, 75.9%-87.1%). After a median follow-up of 13.9 months, the median DOR was NE at the time of analysis.

Overall, 57.1% of the population experienced TEAEs. The most common TEAEs in this trial included dysuria (22.5%), hematuria (8.3%), and urinary tract infections (7.1%).

The primary end point of the ENVISION trial was the 3-month CR rate. Secondary end points included DOR among those with a CR at 3 months.

The FDA previously approved the mitomycin solution for patients with LG-IR-NMIBC in June 2025 based on findings from the ENVISION trial.6

References

  1. Prasad SM, Schoenberg M, Louie MJ, et al. Review of UGN-102: a reverse thermal gel containing mitomycin for the treatment of recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer. Rev Urol. 2025;24(3):exxx.
  2. Chevli KK, Shore ND, Trainer A, et al. Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial. J Urol. 2022;207(1):61-69. doi:10.1097/JU.0000000000002186
  3. Prasad SM, Huang WC, Shore ND, et al. Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 ± transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J Urol. 2023;210(4):619-629. doi:10.1097/JU.0000000000003645
  4. Prasad SM, Shishkov D, Mihaylov NV, et al. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J Urol. 2025;213(2):205-216. doi:10.1097/JU.0000000000004296
  5. ZUSDURI™ clinical review published in Reviews in Urology™ highlights durable efficacy and manageable safety profile in recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. News release. UroGen Pharma Ltd. October 2, 2025. Accessed October 3, 2025. https://tinyurl.com/ynxajy3s
  6. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. News release. FDA. June 12, 2025. Accessed October 3, 2025. https://tinyurl.com/m8xj5pbd
Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content